Clay Siegall is one of the founders of Seattle Genetics. The biotechnology company has been in operations since 1998. Currently, Clay Siegall is the CEO and chairman of the Board of Directors. Under his leadership, the company has realized many achievements. The most notable achievement is the acceleration of FDA approval on cancer treatment therapies based on antibodies.
Dr. Siegall plays a huge role in raising capital for the cancer research ventures. To realize this investment, he collaborates with both public and private companies to fund the research. Currently, he has raised more than $670 million. Before joining Seattle, genetics Clay Siegall worked at Bristol-Meyers Squib Pharmaceutical Research Institute. In addition, he served on both Biomedical Association and the Washington Biotechnology Board of Directors.
Dr. Clay Siegall is serving on the Board of Directors of Alder Biopharmaceuticals, which is a private biotechnology company. He has authored more than 70 publications and is currently dealing with 15 patients.
Dr. Clay is an alumnus of the University of Maryland. Clay got his Bachelor of Science degree in Zoology from the same institution. Moreover, he holds a Ph.D. in Genetics from George Washington University. Seattle Genetics Company is mainly concerned with the development of antibody-based cancer therapies for treatment of cancer and autoimmune diseases. The company is the best in antibody technologies. It develops commercial drugs for patients across the globe beside the US market.
In achieving this objective of eradicating cancer, it has collaborated with other biotech companies. The most notable collaborations are with Genentech. The partnership has raised more than $860 million. The ADC collaborations include Bayer, Progenics, Meddlemmune and Cura Gen together they have added $65 million in capital.
The modern world needs advanced medical solutions that can offer the best treatments for patients. The efforts realized in developing autoimmune diseases and cancer drugs will go a long way in ensuring that patients are cancer free. In turn, this will increase the lifespan of many patients. Clay Siegall is currently one of the 21st-century role models because of his never giving up attitude and persistence. His work will affect many patients in the coming years.